A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

In patients with advanced or recurrent endometrial cancer (EC) with previous exposure to carboplatin and paclitaxel (PT), ...

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...